Results for the First Quarter 2020

Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

Read more

Annual Report 2019

We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

Read more

The REQUEST study is now published

The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

Read more

Investor Presentation, March 3

Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this…

Read more

MiraQ approved for sale in Canada

MiraQ™ is Medistim's newest generation of products for quality assurance within  vascular and cardiac surgery. The system is based on ultrasound, and combines quantitative blood flow volume through transit time flow measurement (TTFM)  with morphological…

Read more